Literature DB >> 16028149

Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.

Conan MacDougall1, J Patrick Powell, Christopher K Johnson, Michael B Edmond, Ronald E Polk.   

Abstract

BACKGROUND: Fluoroquinolones are widely prescribed in hospitals and the community. Previous studies have shown associations between fluoroquinolone use and isolation of fluoroquinolone-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). We performed an ecologic-level study to determine whether variability in hospital percentages of fluoroquinolone-resistant E. coli and MRSA were associated with fluoroquinolone use in hospitals and their surrounding communities.
METHODS: We measured fluoroquinolone use in 17 US hospitals and their surrounding communities in the year 2000. Data on fluoroquinolone use in hospitals was electronically extracted from billing data. Data on fluoroquinolone use in communities was obtained from IMS health data for all prescriptions filled in pharmacies within a 16-km radius of each hospital. We used hospital antibiograms to determine the percentage of isolates that were fluoroquinolone-resistant E. coli and MRSA, and we performed linear regression to determine the relationship between percentage of resistant isolates and fluoroquinolone use in hospitals and their surrounding communities.
RESULTS: There was a significant association between total fluoroquinolone use within hospitals and percentage of S. aureus isolates that were MRSA (r=0.77; P=.0003) and between total fluoroquinolone use in the community and percentage of E. coli isolates that were fluoroquinolone-resistant E. coli (r=0.68; P=.003). Population density within the 16-km radius also correlated with MRSA percentage (r=0.57; P=.015) and fluoroquinolone-resistant E. coli percentage (r=0.85; P=.002), but associations between total fluoroquinolone use and resistance remained significant after adjustment for population density.
CONCLUSIONS: In this ecologic analysis, we found associations between fluoroquinolone use in hospitals and methicillin resistance in S. aureus and between fluoroquinolone use in communities and fluoroquinolone resistance in E. coli in hospitals. Antimicrobial use in hospitals and communities may have different relative importance with regard to resistance in different pathogens encountered in hospitals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028149     DOI: 10.1086/432056

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  47 in total

1.  Validating hospital antibiotic purchasing data as a metric of inpatient antibiotic use.

Authors:  Charlie Tan; Michael Ritchie; Jason Alldred; Nick Daneman
Journal:  J Antimicrob Chemother       Date:  2015-11-05       Impact factor: 5.790

2.  Guideline-concordant antibiotic prescribing for pediatric outpatients with otitis media, community-acquired pneumonia, and skin and soft tissue infections in a large multispecialty healthcare system.

Authors:  Ezzeldin A Saleh; Darrell R Schroeder; Andrew C Hanson; Ritu Banerjee
Journal:  Clin Res Infect Dis       Date:  2015-01-10

3.  Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.

Authors:  Thomas M Hooton; Pacita L Roberts; Ann E Stapleton
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

4.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Staphylococcus aureus strains isolated from bloodstream infections changed significantly in 2006.

Authors:  Nathalie van der Mee-Marquet; Christophe Epinette; Jeremy Loyau; Laurence Arnault; Anne-Sophie Domelier; Barbara Losfelt; Nicole Girard; Roland Quentin
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

Review 6.  Antibiotic use and population ecology: how you can reduce your "resistance footprint".

Authors:  David M Patrick; James Hutchinson
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

7.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

8.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

9.  Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004.

Authors:  E Meyer; F Schwab; P Gastmeier; H Rueden; F D Daschner
Journal:  Infection       Date:  2006-12       Impact factor: 3.553

Review 10.  Population mobility, globalization, and antimicrobial drug resistance.

Authors:  Douglas W MacPherson; Brian D Gushulak; William B Baine; Shukal Bala; Paul O Gubbins; Paul Holtom; Marisel Segarra-Newnham
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.